SyntheticMR reported a 38% drop in 2024 sales and a net loss, impacted by market headwinds and organizational changes. The Combinostics acquisition and new product approvals position the company for recovery and cost savings in 2025.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.